Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype
JACC: Heart Failure · 2023
DOI: 10.1016/j.jchf.2023.05.010 ↗Kurz gefasst
Fachartikel in der Zeitschrift JACC: Heart Failure, 2023. Verfasst von Mikhail N Kosiborod und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Disease, Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City School of Medicine, Kansas City, M…. Hauptthemen laut MEDLINE: Heart Failure, Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 80-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novo Nordisk.
Abstract (Originalsprache)
BACKGROUND: The majority of patients with heart failure with preserved ejection fraction (HFpEF) have the obesity phenotype, but no therapies specifically targeting obesity in HFpEF exist. OBJECTIVES: The aim of this study was to describe the design and baseline characteristics of 2 trials of semaglutide, a glucagon-like peptide-1 receptor agonist, in patients with the obesity HFpEF phenotype: STEP-HFpEF (Semaglutide Treatment Effect in People with obesity and HFpEF; NCT04788511) and STEP-HFpEF DM (Semaglutide Treatment Effect in People with obesity and HFpEF and type 2 diabetes; NCT04916470). METHODS: Both STEP-HFpEF and STEP-HFpEF DM are international multicenter, double-blind, placebo-controlled trials that randomized adults with HFpEF and a body mass index ≥30 kg/m2 to once-weekly semaglutide at a dose of 2.4 mg or placebo. Participants were eligible if they had a left ventricular ejection fraction (LVEF) ≥45%; NYHA functional class II to IV; a Kansas City Cardiomyopathy Questionnaire (KCCQ)-Clinical Summary Score (CSS)
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular Disease, Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City School of Medicine, Kansas City, Missouri, USA. Electronic address: mkosiborod@saint-lukes.org.
- Novo Nordisk A/S, Søborg, Denmark.
- Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
- Baylor Scott and White Research Institute, Dallas, Texas, USA; Department of Medicine, University of Mississippi, Jackson, Mississippi, USA. Electronic address: https://twitter.com/JavedButler1.
- Diabetes Research Centre, University of Leicester, Leicester, United Kingdom; National Institute for Health Care and Research, Leicester Biomedical Research Centre, Leicester, United Kingdom.
- Department of Internal Medicine, Sections of Cardiovascular Medicine and Geriatrics and Gerontology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
Förderung
- Novo Nordisk
Zitieren
APA
Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Christensen, L., Davies, M., Hovingh, K. G., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., Shah, S. J., Treppendahl, M. B., Verma, S., & Petrie, M. C. (2023). Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype. JACC: Heart Failure. https://doi.org/10.1016/j.jchf.2023.05.010
Vancouver
Kosiborod MN, Abildstrøm SZ, Borlaug BA, Butler J, Christensen L, Davies M, et al. Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype. JACC: Heart Failure. 2023. doi:10.1016/j.jchf.2023.05.010
BibTeX
@article{Kosiborod2023,
author = {Kosiborod, Mikhail N and Abildstrøm, Steen Z and Borlaug, Barry A and Butler, Javed and Christensen, Louise and Davies, Melanie and Hovingh, Kees G and Kitzman, Dalane W and Lindegaard, Marie L and Møller, Daniél Vega and Shah, Sanjiv J and Treppendahl, Marianne Bach and Verma, Subodh and Petrie, Mark C},
title = {Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype},
journal = {JACC: Heart Failure},
year = {2023},
doi = {10.1016/j.jchf.2023.05.010}
}
EUVIMED